Cancel anytime
Apollomics Inc. Warrant (APLMW)APLMW
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: APLMW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 0% | Upturn Advisory Performance 1 | Avg. Invested days: 0 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 0% | Avg. Invested days: 0 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.88M USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - |
Volume (30-day avg) 61968 | Beta - |
52 Weeks Range 0.01 - 0.06 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 27.88M USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - | Volume (30-day avg) 61968 | Beta - |
52 Weeks Range 0.01 - 0.06 | Updated Date 11/20/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 20542439 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 |
Shares Outstanding - | Shares Floating - |
Percent Insiders - | Percent Institutions - |
Trailing PE - | Forward PE - | Enterprise Value 20542439 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding - | Shares Floating - |
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Apollomics Inc. Warrant - Comprehensive Overview
Disclaimer: I am an AI chatbot and cannot provide financial advice. This information is for general knowledge and informational purposes only, and does not constitute professional financial advice.
Please note: As of my current knowledge cut-off in November 2023, Apollomics Inc. has not issued any warrants. The information below is based on the publicly available information about Apollomics Inc. and its common stock.
Company Profile:
History and Background:
- Founded in 2008, Apollomics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for unmet medical needs in oncology and infectious diseases.
- The company focuses on utilizing its proprietary discovery platform to identify and develop first-in-class drug candidates targeting specific enzymes crucial for disease progression.
Core Business Areas:
- Oncology: Apollomics is currently developing several oncology drug candidates, targeting various cancers like pancreatic, ovarian, and triple-negative breast cancer.
- Infectious Diseases: The company is also focusing on developing treatments for difficult-to-treat infectious diseases, particularly focusing on multidrug-resistant bacteria.
Leadership and Corporate Structure:
- Leadership Team: The leadership team comprises experts in drug development, research, and business management. Key members include:
- Dr. Sung-Yum Seo, CEO, brings over 20 years of experience in the biopharmaceutical industry.
- Dr. Jae-Hyun Cheong, Chief Scientific Officer, holds expertise in drug discovery and development.
- Dr. Michael Tong, Chief Medical Officer, is a physician with extensive experience in oncology clinical research.
- Corporate Structure: Apollomics has its headquarters in Seoul, South Korea, with subsidiaries in the United States and China.
Top Products and Market Share:
- As of November 2023, Apollomics does not have any marketed products.
- Their lead oncology drug candidate, APG-115, is currently in Phase I clinical trials for the treatment of pancreatic cancer.
- The company also has several other drug candidates in preclinical development stages.
Total Addressable Market:
- The global oncology market is expected to reach USD 314.57 billion by 2026, growing at a CAGR of 10.4%.
- The global market for anti-infective drugs is estimated to reach USD 27.55 billion by 2028, with a CAGR of 8.5%.
Financial Performance:
As Apollomics is a clinical-stage company with no marketed products, it has not yet generated any revenue. The company's financial performance is primarily driven by research and development expenses, administrative costs, and funding activities.
Growth Trajectory:
- Apollomics is in the early stages of development and faces significant challenges in bringing its drug candidates to market.
- The company's future success depends on the successful completion of clinical trials and regulatory approvals for its drug candidates.
Market Dynamics:
- The oncology and infectious diseases markets are highly competitive, with numerous players developing innovative therapies.
- Apollomics needs to differentiate its products based on efficacy, safety, and cost-effectiveness to gain market share.
Competitors:
- Key competitors in the oncology market include Bristol Myers Squibb (BMY), Pfizer (PFE), Merck (MRK), Roche (RHHBY), and AstraZeneca (AZN).
- Major competitors in the infectious diseases market include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), and Johnson & Johnson (JNJ).
Recent Acquisitions:
- Apollomics does not have any acquisitions in the past three years.
AI-Based Fundamental Rating:
- An AI-based fundamental rating for Apollomics would depend on various factors, including its financial health, market position, and future prospects.
- Given the company's early stage of development, its lack of revenue, and significant competition, an AI model might assign a relatively conservative rating. However, the potential market opportunity and innovative drug candidates could also contribute to a more optimistic rating.
Sources and Disclaimers:
- Information for this overview was gathered from various sources, including:
- Apollomics Inc. website
- SEC filings
- Market research reports
- News articles
This information is provided for general knowledge and informational purposes only, and does not constitute professional financial advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apollomics Inc. Warrant
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 2021-11-26 | CEO | - |
Sector | Healthcare | Website | |
Industry | Biotechnology | Full time employees | 59 |
Headquaters | - | ||
CEO | - | ||
Website | |||
Website | |||
Full time employees | 59 |
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.